nach oben

Erschienen in:

01.04.2016

Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment

verfasst von: Mariana Campderá, Nuria Palacios, Javier Aller, Rosa Magallón, Paloma Martín, Gertrudis Saucedo, Howard Lilienfeld, Javier Estrada

Erschienen in: Pituitary | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Temozolomide (TMZ) is an oral alkylating agent that has been used over the past 8 years to treat aggressive pituitary tumors resistant to conventional therapy. To date, only 25 patients treated with TMZ for ACTH producing pituitary tumors (14 adenomas and 11 carcinomas) have been reported.

Materials and Methods

We present a retrospective review of the medical records of three patients with aggressive ACTH producing adenomas treated with TMZ. In the three cases there was evidence of progression to conventional therapy before starting TMZ. We used the conventional scheme for the treatment of gliomas until completing 7, 12 and 6 cycles respectively. Reduction in tumor size was evident after the 3rd, 5th and 4th cycle of TMZ and progression free survival was 25, 19 and more than 12 months in the three patients respectively. Improvement of the ocular and visual symptoms was evident after the 4th cycle of treatment in all cases. Normalization of urinary free cortisol levels was achieved after the 3rd and 9th cycle in the two cases with hypercortisolism. Two of the three patients received a second course of treatment when the disease progressed but it did not stop tumor progression. The principal side effects were G3 neutropenia, G1 and G2 thrombocytopenia, G1 lymphopenia, asthenia and nausea.

Conclusion

The treatment with TMZ is effective and safe in patients with aggressive corticotrophin tumors resistant to conventional therapy. Nevertheless once the disease progresses, a second course of treatment does not seem to be effective.

Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing’s syndrome. Lancet 367(9522):1605–1617CrossRefPubMed

Estrada J, Boronat M, Mielgo M, Magallón R, Millán I, Díez S, Lucas T, Barceló B (1997) The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med 336(3):172–177. doi:10.1056/NEJM199701163360303 CrossRefPubMed

McCormack AI, Wass JAH, Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 41(10):1133–1148. doi:10.1111/j.1365-2362.2011.02520.x CrossRefPubMed

Dillard TH, Gultekin SH, Delashaw JB, Yedinak CG, Neuwelt EA, Fleseriu M (2011) Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary 14(1):80–91. doi:10.1007/s11102-010-0264-1 CrossRefPubMed

Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L (2007) Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 56(4):275–287. doi:10.1016/j.phrs.2007.08.003 CrossRefPubMed

Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC (2008) MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115(2):261–262. doi:10.1007/s00401-007-0279-5 CrossRefPubMed

Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A (2013) DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 98(3):1130–1136. doi:10.1210/jc.2012-2924 CrossRefPubMed

Al-Shraim M, Asa SL (2006) The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol 111(1):1–7. doi:10.1007/s00401-005-1093-6 CrossRefPubMed

Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville J-F, Assaker R, Auger C, Brue T, Cornelius A, Dufour H, Jouanneau E, François P, Galland F, Mougel F, Chapuis F, Villeneuve L, Maurage C-A, Figarella-Branger D, Raverot G, Barlier A, Bernier M, Bonnet F, Borson-Chazot F, Brassier G, Caulet-Maugendre S, Chabre O, Chanson P, Cottier JF, Delemer B, Delgrange E, Di Tommaso L, Eimer S, Gaillard S, Jan M, Girard JJ, Lapras V, Loiseau H, Passagia JG, Patey M, Penfornis A, Poirier JY, Perrin G, Tabarin A (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123–135. doi:10.1007/s00401-013-1084-y CrossRefPubMed

10.

Pizarro CB, Oliveira MC, Coutinho LB, Ferreira NP, Alegre P (2004) Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Braz J Med Biol Res 37:235–243CrossRefPubMed

11.

Ramírez C, Cheng S, Vargas G, Asa SL, Ezzat S, González B, Cabrera L, Guinto G, Mercado M (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 97(5):1745–1751. doi:10.1210/jc.2011-3163 CrossRefPubMed

12.

McCormack A, Raverot G (2013) Temozolomide and aggressive pituitary tumours: longer-term follow up. Paper presented at the 13th International Pituitary Congress, San Francisco

13.

Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38(4):761–765CrossRef

14.

Hentschel SJ, McCutcheon IE, Moore W, Durity FA (2003) P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci 30(3):215–219CrossRefPubMed

15.

Mete O, Ezzat S, Asa SL (2012) Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol. doi:10.1530/JME-12-0113 PubMed

16.

Edwards A, Swords F, Plowman PN (2009) Focal radiation therapy for patients with persistent/recurrent pituitary adenoma, despite previous radiotherapy. Pituitary 12(1):30–34. doi:10.1007/s11102-008-0115-5 CrossRefPubMed

17.

Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, Colquhoun I, Lewis P, Brampton MH (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40(6):484–488CrossRefPubMed

18.

Aller Pardo J, Campderá Michelena M, Palacios García N, Estrada García J (2015) Actualización en neuroendocrinología. Elsevier, España

19.

Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E, Kovacs K (2006) Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol 65(4):552–553. doi:10.1111/j.1365-2265.2006.02653.x CrossRef

20.

Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P, Reni M (2010) Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 163:843–851CrossRefPubMed

21.

Takeshita A, Inoshita N, Taguchi M, Okuda C, Fukuhara N, Oyama K, Ohashi K, Sano T, Takeuchi Y, Yamada S (2009) High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing’s disease. Eur J Endocrinol 161(4):553–559. doi:10.1530/EJE-09-0414 CrossRefPubMed

22.

Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26(25):4189–4199. doi:10.1200/JCO.2007.11.5964 CrossRefPubMed

23.

Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA, Vance ML, Thorner MO, Laws ER, Lopes MBS (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95(11):E280–E290. doi:10.1210/jc.2010-0441 CrossRefPubMed

24.

Matsuno A, Murakami M, Hoya K, Yamada SM, Miyamoto S, Yamada S, Son J-H, Nishido H, Ide F, Nagashima H, Sugaya M, Hirohata T, Mizutani A, Okinaga H, Ishii Y, Tahara S, Teramoto A, Osamura RY (2013) Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide. Med Mol Morphol. doi:10.1007/s00795-013-0050-z PubMed

25.

Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y, Fine RL (2011) Temozolomide (Temodar^®) and capecitabine (Xeloda^®) treatment of an aggressive corticotroph pituitary tumor. Pituitary 14(4):418–424. doi:10.1007/s11102-009-0211-1 CrossRefPubMedPubMedCentral

26.

Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M, Remotti H, Lignelli A, Fine RL (2013) High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing’s disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery. doi:10.1227/NEU.0000000000000251 PubMed

27.

Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP, Thomé C (2010) SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes 118(10):760–763. doi:10.1055/s-0030-1253419 CrossRefPubMed

28.

Cooper O, Geroge V, Hidenori F, Green MI, Melmed S (2011) Expression and function of ErbB receptors and ligands in the pituitary. Endocr Relat Cancer. doi:10.1530/ERC-11-0066.Expression PubMedPubMedCentral

29.

Fukuoka H, Cooper O, Ben-shlomo A, Mamelak A, Ren S-G, Bruyette D, Melmed S (2011) EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Investig 121(12):4712. doi:10.1172/JCI60417DS1 CrossRefPubMedPubMedCentral

30.

Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, Meitinger T, Mizuno-Yamasaki E, Kawaguchi K, Saeki Y, Tanaka K, Wieland T, Graf E, Saeger W, Ronchi CL, Allolio B, Buchfelder M, Strom TM, Fassnacht M, Komada M (2014) Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet. doi:10.1038/ng.3166 PubMed

31.

Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, Rotondo F, Horvath E, Kovacs K (2012) Anti-VEGF therapy in pituitary carcinoma. Pituitary 15(3):445–449. doi:10.1007/s11102-011-0346-8 CrossRefPubMed

Titel: Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment
verfasst von: Mariana Campderá
Nuria Palacios
Javier Aller
Rosa Magallón
Paloma Martín
Gertrudis Saucedo
Howard Lilienfeld
Javier Estrada
Publikationsdatum: 01.04.2016
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 2/2016
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-015-0694-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Materials and Methods

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas

A prospective study of appetite and food craving in 30 patients with Cushing’s disease

New oral anticoagulants and pituitary apoplexy

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study

Comprehensive evaluation of thyrotropinomas: single-center 20-year experience